545 related articles for article (PubMed ID: 24727384)
1. Prostate-specific antigen and other serum and urine markers in prostate cancer.
Stephan C; Ralla B; Jung K
Biochim Biophys Acta; 2014 Aug; 1846(1):99-112. PubMed ID: 24727384
[TBL] [Abstract][Full Text] [Related]
2. Current biomarkers for diagnosing of prostate cancer.
Stephan C; Jung K; Ralla B
Future Oncol; 2015; 11(20):2743-55. PubMed ID: 26358139
[TBL] [Abstract][Full Text] [Related]
3. [New biomarkers in serum and urine for detection of prostate cancer].
Stephan C; Jung K; Miller K; Ralla B
Aktuelle Urol; 2015 Mar; 46(2):129-43. PubMed ID: 25897535
[TBL] [Abstract][Full Text] [Related]
4. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
5. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.
Sanguedolce F; Cormio A; Brunelli M; D'Amuri A; Carrieri G; Bufo P; Cormio L
Clin Genitourin Cancer; 2016 Apr; 14(2):117-21. PubMed ID: 26774207
[TBL] [Abstract][Full Text] [Related]
6. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
[TBL] [Abstract][Full Text] [Related]
7. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
[TBL] [Abstract][Full Text] [Related]
8. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.
Filella X; Foj L
Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27792187
[TBL] [Abstract][Full Text] [Related]
9. Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa).
Stephan C; Rittenhouse H; Hu X; Cammann H; Jung K
EJIFCC; 2014 Apr; 25(1):55-78. PubMed ID: 27683457
[TBL] [Abstract][Full Text] [Related]
10. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
11. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
Hendriks RJ; van Oort IM; Schalken JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
[TBL] [Abstract][Full Text] [Related]
12. Clinical use of novel urine and blood based prostate cancer biomarkers: a review.
Dijkstra S; Mulders PF; Schalken JA
Clin Biochem; 2014 Jul; 47(10-11):889-96. PubMed ID: 24177197
[TBL] [Abstract][Full Text] [Related]
13. Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer.
Cao L; Lee CH; Ning J; Handy BC; Wagar EA; Meng QH
Arch Pathol Lab Med; 2018 Sep; 142(9):1106-1112. PubMed ID: 29547000
[TBL] [Abstract][Full Text] [Related]
14. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
[TBL] [Abstract][Full Text] [Related]
15. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
[TBL] [Abstract][Full Text] [Related]
16. The role of prostate cancer biomarkers in undiagnosed men.
Dani H; Loeb S
Curr Opin Urol; 2017 May; 27(3):210-216. PubMed ID: 28212119
[TBL] [Abstract][Full Text] [Related]
17. Emerging biomarkers in the detection and prognosis of prostate cancer.
Filella X; Foj L
Clin Chem Lab Med; 2015 Jun; 53(7):963-73. PubMed ID: 25581761
[TBL] [Abstract][Full Text] [Related]
18. Beyond PSA: The Role of Prostate Health Index (phi).
Ferro M; De Cobelli O; Lucarelli G; Porreca A; Busetto GM; Cantiello F; Damiano R; Autorino R; Musi G; Vartolomei MD; Muto M; Terracciano D
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32053990
[TBL] [Abstract][Full Text] [Related]
19. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue.
Stephan C; Jung M; Rabenhorst S; Kilic E; Jung K
Clin Chem Lab Med; 2015 Jun; 53(7):1109-18. PubMed ID: 25720086
[TBL] [Abstract][Full Text] [Related]
20. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
